12.00 – 12.10 – Opening of the conference. Introduction of the conference participants.

12.15 – 12.45 – New generation of inhibitors of Bruton tyrosine kinase. What we know after a year of usage in Russia – E.A. Nikitin (Moscow).  Sponsor: AstraZeneca. No “continuous medical education” points are granted.

12.45 – 13.15 – Diffuse alveolar hemorrhage in leukemia patients – Хуйбо Ли (Harbin, China). Sponsor: Irkutsk State Medical University.  No “continuous medical education” points are granted.

13.15 – 13.45 – State of the art and achievements in treatment of chronic lymphocytic leukemia – Хунцзюань Юй  (Harbin, China). Sponsor: Irkutsk State Medical University.  No “continuous medical education” points are granted.

13.45 – 14.05 – Experience of clinical application of Imbruvica – N.O. Saraeva (Irkutsk).   Sponsor: Janssen. No “continuous medical education” points are granted.

14.20 – 14.50 – To whom? When? How? Practical aspects of using Akalabrutinibum – A.A. Petrenko (Moscow).  Sponsor: AstraZeneca. No “continuous medical education” points are granted.

14.25 – 14.55 – First-line therapy of CLL: personalized approach to patients – E.A. Stadnik (Saint-Petersburg). Sponsor: Janssen. No “continuous medical education” points are granted.

14.55 – 15.15 – Comorbidities in blood cancer patients. Opinion of a cardiologist – V.A. Ionin (Saint-Petersburg). Sponsor: AstraZeneca. No “continuous medical education” points are granted.

14.25 – 14.55 – Obinutuzumabum in first-line therapy of CLL: new objectives and options – E.A. Stadnik (Saint-Petersburg). Sponsor: JSC Roche-Moscow.  No “continuous medical education” points are granted.

15.45 – 16.00 – Discussion.